Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2013 3
2014 1
2015 1
2016 4
2017 6
2018 8
2019 2
2020 3
2021 5
2022 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
Davis SL, Messersmith WA, Purcell WT, Lam ET, Corr BR, Leal AD, Lieu CH, O'Bryant CL, Smoots SG, Dus ED, Jordan KR, Serkova NJ, Pitts TM, Diamond JR. Davis SL, et al. Among authors: purcell wt. Cancers (Basel). 2024 Apr 10;16(8):1456. doi: 10.3390/cancers16081456. Cancers (Basel). 2024. PMID: 38672538 Free PMC article.
One partial response to treatment was observed in a patient with ER positive breast cancer, and a patient with pancreatic cancer experienced prolonged stable disease. In an additional cohort of pancreatic cancer patients, treatment response was modest. ...
One partial response to treatment was observed in a patient with ER positive breast cancer, and a patient with pancreatic cancer …
Development of a reference chart for monitoring cancer-related fatigue throughout a supervised exercise program.
Marker RJ, Kittelson AJ, Jankowski CM, Scorsone JJ, Peters JC, Purcell WT. Marker RJ, et al. Among authors: purcell wt. Rehabil Oncol. 2022 Apr;40(2):82-88. doi: 10.1097/01.reo.0000000000000285. Rehabil Oncol. 2022. PMID: 35711819 Free PMC article.
BACKGROUND: Cancer-related fatigue (CRF) is one of the most reported and functionally limiting symptoms experienced by individuals living with and beyond cancer. ...No cancer types were excluded and individuals were either undergoing chemotherapy and/or radia …
BACKGROUND: Cancer-related fatigue (CRF) is one of the most reported and functionally limiting symptoms experienced by individuals li …
Psychotropic medications in oncology.
Biringen EK, Cox-Martin E, Niemiec S, Wood C, Purcell WT, Kolva E. Biringen EK, et al. Among authors: purcell wt. Support Care Cancer. 2021 Nov;29(11):6801-6806. doi: 10.1007/s00520-021-06283-w. Epub 2021 May 15. Support Care Cancer. 2021. PMID: 33993408
CONTEXT: Psychological distress is common in patients with cancer, and oncology providers are often tasked with utilizing psychotropic medications to treat such symptoms. ...METHODS: A cross-sectional survey was sent to oncology medical doctors, nurse practitioners, and ph …
CONTEXT: Psychological distress is common in patients with cancer, and oncology providers are often tasked with utilizing psychotropi …
Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers.
Kastelowitz N, Marsh MD, McCarter M, Meguid RA, Bhardwaj NW, Mitchell JD, Weyant MJ, Scott C, Schefter T, Stumpf P, Leong S, Messersmith W, Lieu C, Leal AD, Davis SL, Purcell WT, Kane M, Wani S, Shah R, Hammad H, Edmundowicz S, Goodman KA. Kastelowitz N, et al. Among authors: purcell wt. Front Oncol. 2021 Mar 10;11:614640. doi: 10.3389/fonc.2021.614640. eCollection 2021. Front Oncol. 2021. PMID: 33777751 Free PMC article.
Introduction: The impact of radiation prescription dose on postoperative complications during standard of care trimodality therapy for operable stage II-III esophageal and gastroesophageal junction cancers has not been established. Methods: We retrospectively reviewed 82 p …
Introduction: The impact of radiation prescription dose on postoperative complications during standard of care trimodality therapy for opera …
Status of Cancer Care at Network Sites of the Nation's Academic Cancer Centers.
Gerson SL, Shaw K, Harrison LB, Holcombe RF, Hutchins L, Lee CB, Loehrer PJ, Mulkerin D, Purcell WT, Teston L, Weiner LM, Weiner GJ. Gerson SL, et al. Among authors: purcell wt. J Natl Compr Canc Netw. 2021 Mar 11;19(6):726-732. doi: 10.6004/jnccn.2020.7656. J Natl Compr Canc Netw. 2021. PMID: 33706258 Free PMC article.
BACKGROUND: Cancer care coordination across major academic medical centers and their networks is evolving rapidly, but the spectrum of organizational efforts has not been described. ...Certification program participation varied extensively across networks. CONCLUSIONS: The …
BACKGROUND: Cancer care coordination across major academic medical centers and their networks is evolving rapidly, but the spectrum o …
Predictors of attendance during an exercise program for cancer survivors.
Leach HJ, Marker RJ, Scorsone JJ, Peters JC, Purcell WT. Leach HJ, et al. Among authors: purcell wt. Support Care Cancer. 2021 Jul;29(7):3425-3428. doi: 10.1007/s00520-021-06057-4. Epub 2021 Feb 16. Support Care Cancer. 2021. PMID: 33594510
PURPOSE: Exercise programs delivered in community- or clinic-based settings improve physical and psychosocial outcomes among cancer survivors; however, adherence is essential to achieve such benefits. This study examined predictors of attendance to an exercise program in a …
PURPOSE: Exercise programs delivered in community- or clinic-based settings improve physical and psychosocial outcomes among cancer s …
Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial.
Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Pusca IA, Beg MS, Purcell WT, Croitoru AE, Ilieva RN, Natošević S, Nita AL, Kalev DN, Harpaz Z, Farbstein M, Silverman MH, Bristol D, Itzhak I, Fishman P. Stemmer SM, et al. Among authors: purcell wt. Cancers (Basel). 2021 Jan 7;13(2):187. doi: 10.3390/cancers13020187. Cancers (Basel). 2021. PMID: 33430312 Free PMC article.
Effects of a Clinic-Based Exercise Program on Sleep Disturbance Among Cancer Survivors.
Hidde MC, Leach HJ, Marker RJ, Peters JC, Purcell WT. Hidde MC, et al. Among authors: purcell wt. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420975852. doi: 10.1177/1534735420975852. Integr Cancer Ther. 2020. PMID: 33243013 Free PMC article.
INTRODUCTION: Sleep disturbance is the second leading negative side effect reported by cancer survivors, and evidence exists to suggest that exercise may improve sleep for cancer survivors. ...To be eligible, individuals had to be diagnosed with cancer, and u …
INTRODUCTION: Sleep disturbance is the second leading negative side effect reported by cancer survivors, and evidence exists to sugge …
Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Patil T, et al. Among authors: purcell wt. Front Oncol. 2020 Apr 15;10:510. doi: 10.3389/fonc.2020.00510. eCollection 2020. Front Oncol. 2020. PMID: 32351892 Free PMC article.
Background: Osimertinib is a 3rd-generation tyrosine kinase inhibitor (TKI) that blocks the epidermal growth factor receptor (EGFR) in non-small lung cancer (NSCLC) and has dramatically improved outcomes for patients with EGFR mutations. ...
Background: Osimertinib is a 3rd-generation tyrosine kinase inhibitor (TKI) that blocks the epidermal growth factor receptor (EGFR) in non-s …
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Patil T, et al. Among authors: purcell wt. Clin Lung Cancer. 2020 May;21(3):e191-e204. doi: 10.1016/j.cllc.2019.11.008. Epub 2019 Nov 21. Clin Lung Cancer. 2020. PMID: 31859066 Free PMC article.
Pilot Prehabilitation Program for Patients With Esophageal Cancer During Neoadjuvant Therapy and Surgery.
Dewberry LC, Wingrove LJ, Marsh MD, Glode AE, Schefter TE, Leong S, Purcell WT, McCarter MD. Dewberry LC, et al. Among authors: purcell wt. J Surg Res. 2019 Mar;235:66-72. doi: 10.1016/j.jss.2018.09.060. Epub 2018 Oct 23. J Surg Res. 2019. PMID: 30691852
BACKGROUND: Locally advanced esophageal cancer is often treated with neoadjuvant therapy followed by surgery. Many patients present with or experience clinical deconditioning during neoadjuvant therapy. ...The aims of this study were to evaluate the feasibility of a pilot …
BACKGROUND: Locally advanced esophageal cancer is often treated with neoadjuvant therapy followed by surgery. Many patients present w …
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. Patil T, et al. Among authors: purcell wt. J Thorac Oncol. 2018 Nov;13(11):1717-1726. doi: 10.1016/j.jtho.2018.07.001. Epub 2018 Jul 5. J Thorac Oncol. 2018. PMID: 29981925 Free PMC article.
INTRODUCTION: Central nervous system (CNS) metastases in lung cancer are a frequent cause of morbidity and mortality. There are conflicting data on the incidence of CNS metastases in stage IV ROS1-positive NSCLC and the rate of CNS progression during crizotinib therapy. .. …
INTRODUCTION: Central nervous system (CNS) metastases in lung cancer are a frequent cause of morbidity and mortality. There are confl …
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer.
McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. McCoach CE, et al. Among authors: purcell wt. Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10. Clin Cancer Res. 2018. PMID: 29636358 Free PMC article.
Purpose: Despite initial benefit from tyrosine kinase inhibitors (TKIs), patients with advanced non-small cell lung cancer (NSCLC) harboring ALK (ALK(+)) and ROS1 (ROS1(+)) gene fusions ultimately progress. ...Our data suggest that a focus on KDMs will miss most resistance …
Purpose: Despite initial benefit from tyrosine kinase inhibitors (TKIs), patients with advanced non-small cell lung cancer (NSCLC) ha …
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. McCoach CE, et al. Among authors: purcell wt. Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29. Clin Cancer Res. 2018. PMID: 29599410 Free PMC article.
Purpose: Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors (ALKi). ...In 6 patients with known EGFR-activating mutations, an ALK fusion was identified on pr …
Purpose: Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (ALK) gene fusions …
Evaluation of the effects of a clinically implemented exercise program on physical fitness, fatigue, and depression in cancer survivors.
Marker RJ, Cox-Martin E, Jankowski CM, Purcell WT, Peters JC. Marker RJ, et al. Among authors: purcell wt. Support Care Cancer. 2018 Jun;26(6):1861-1869. doi: 10.1007/s00520-017-4019-7. Epub 2017 Dec 21. Support Care Cancer. 2018. PMID: 29270829
PURPOSE: Despite national recommendations, exercise programs are still not clinically implemented as standard of care for cancer survivors. This investigation examined the effects of a clinically implemented and personalized exercise program on physical fitness, fatigue, a …
PURPOSE: Despite national recommendations, exercise programs are still not clinically implemented as standard of care for cancer surv …
Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer.
Robin TP, Camidge DR, Stuhr K, Nath SK, Breeze RE, Pacheco JM, Liu AK, Gaspar LE, Purcell WT, Doebele RC, Kavanagh BD, Rusthoven CG. Robin TP, et al. Among authors: purcell wt. J Thorac Oncol. 2018 May;13(5):715-720. doi: 10.1016/j.jtho.2017.12.006. Epub 2017 Dec 19. J Thorac Oncol. 2018. PMID: 29269007 Free article.
METHODS: We reviewed the cases of patients with EGFR-mutated and ALK-rearranged NSCLC presenting to our cancer center between 2008 and 2017 and included only patients receiving treatment to four or more BMs in a single radiosurgery session. ...
METHODS: We reviewed the cases of patients with EGFR-mutated and ALK-rearranged NSCLC presenting to our cancer center between 2008 an …
Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database.
Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Schefter T, Goodman KA. Amini A, et al. Among authors: purcell wt. Pancreas. 2017 Aug;46(7):904-912. doi: 10.1097/MPA.0000000000000876. Pancreas. 2017. PMID: 28697131 Free PMC article.
OBJECTIVES: The role of radiotherapy (RT) in locally advanced pancreatic cancer (LAPC) is uncertain. This study examines patterns of care and survival outcomes of LAPC undergoing chemotherapy alone versus chemotherapy plus RT (C + RT). METHODS: The National Cancer D …
OBJECTIVES: The role of radiotherapy (RT) in locally advanced pancreatic cancer (LAPC) is uncertain. This study examines patterns of …
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Gray JE, et al. Among authors: purcell wt. Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5. Clin Cancer Res. 2017. PMID: 28679770 Clinical Trial.
Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1-7) mSCLC who received either 8 or 10 mg/kg …
Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experim …
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Heist RS, et al. Among authors: purcell wt. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26. J Clin Oncol. 2017. PMID: 28548889 Clinical Trial.
Purpose Trop-2, expressed in most solid cancers, may be a target for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC). ...
Purpose Trop-2, expressed in most solid cancers, may be a target for antibody-drug conjugates (ADCs) in non-small-cell lung cancer …
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. Shields PG, et al. Among authors: purcell wt. J Natl Compr Canc Netw. 2016 Nov;14(11):1430-1468. doi: 10.6004/jnccn.2016.0152. J Natl Compr Canc Netw. 2016. PMID: 27799513
Cigarette smoking has been implicated in causing many cancers and cancer deaths. There is mounting evidence indicating that smoking negatively impacts cancer treatment efficacy and overall survival. The NCCN Guidelines for Smoking Cessation have been created …
Cigarette smoking has been implicated in causing many cancers and cancer deaths. There is mounting evidence indicating that sm …
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Chabon JJ, et al. Among authors: purcell wt. Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815. Nat Commun. 2016. PMID: 27283993 Free PMC article.
Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib. ...
Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with …
Perioperative Mortality in Nonelderly Adult Patients With Cancer: A Population-based Study Evaluating Health Care Disparities in the United States According to Insurance Status.
Amini A, Yeh N, Jones BL, Bedrick E, Vinogradskiy Y, Rusthoven CG, Amini A, Purcell WT, Karam SD, Kavanagh BD, Guntupalli SR, Fisher CM. Amini A, et al. Among authors: purcell wt. Am J Clin Oncol. 2018 May;41(5):476-484. doi: 10.1097/COC.0000000000000306. Am J Clin Oncol. 2018. PMID: 27281264
OBJECTIVES: The purpose of this study was to evaluate whether insurance status predicts for perioperative mortality (death within 30 d of cancer-directed surgery) for the 20 most common surgically treated cancers. METHODS: The SEER database was examined for the 20 m …
OBJECTIVES: The purpose of this study was to evaluate whether insurance status predicts for perioperative mortality (death within 30 d of …
Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Patil T, et al. Among authors: purcell wt. Lung Cancer. 2016 Jun;96:27-32. doi: 10.1016/j.lungcan.2016.03.007. Epub 2016 Mar 26. Lung Cancer. 2016. PMID: 27133746
INTRODUCTION: Peritoneal metastasis from lung cancer is an uncommon clinical event and there are limited data on what factors predict peritoneal progression. This study retrospectively investigated whether patterns of metastatic spread and oncogene status in patients with …
INTRODUCTION: Peritoneal metastasis from lung cancer is an uncommon clinical event and there are limited data on what factors predict …
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Rudek MA, et al. Among authors: purcell wt. J Clin Pharmacol. 2016 Aug;56(8):966-73. doi: 10.1002/jcph.681. Epub 2016 Feb 2. J Clin Pharmacol. 2016. PMID: 26632033 Free PMC article. Clinical Trial.
A nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics in patients with advanced colorectal cancer …
A nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conduc …
Subacute headache in a patient with metastatic gastric cancer.
Batley KE, Schade H, Purcell WT. Batley KE, et al. Among authors: purcell wt. Oncology (Williston Park). 2015 May;29(5):390, C3. Oncology (Williston Park). 2015. PMID: 25979548 Free article. No abstract available.
A newly discovered liver mass in a 65-year-old woman.
McKean M, Purcell WT. McKean M, et al. Among authors: purcell wt. Oncology (Williston Park). 2013 Nov;27(11):1162-3, C3. Oncology (Williston Park). 2013. PMID: 24575546 Free article. No abstract available.
A large cystic pancreatic mass in a 45-year-old female.
Lammers A, McManus MC, Purcell WT. Lammers A, et al. Among authors: purcell wt. Oncology (Williston Park). 2013 Jul;27(7):669, 674. Oncology (Williston Park). 2013. PMID: 23977762 Free article. No abstract available.
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.
Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Weickhardt AJ, et al. Among authors: purcell wt. Cancer. 2013 Jul 1;119(13):2383-90. doi: 10.1002/cncr.28089. Epub 2013 Apr 12. Cancer. 2013. PMID: 23585220 Free PMC article.
The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not been previously reported. METHODS: Male cancer patients treated with crizotinib had total testosterone levels measured and results compa …
The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not bee …
Novel antifolate drugs.
Purcell WT, Ettinger DS. Purcell WT, et al. Curr Oncol Rep. 2003 Mar;5(2):114-25. doi: 10.1007/s11912-003-0098-3. Curr Oncol Rep. 2003. PMID: 12583828 Review.
Development of matrix metalloproteinase inhibitors in cancer therapy.
Purcell WT, Rudek MA, Hidalgo M. Purcell WT, et al. Hematol Oncol Clin North Am. 2002 Oct;16(5):1189-227. doi: 10.1016/s0889-8588(02)00044-8. Hematol Oncol Clin North Am. 2002. PMID: 12512389 Review.
The matrix metalloproteinases represent an attractive target for cancer treatment, and a number of matrix metalloproteinase inhibitors are undergoing clinical trials. ...
The matrix metalloproteinases represent an attractive target for cancer treatment, and a number of matrix metalloproteinase inhibitor …
Evolving therapies: farnesyltransferase inhibitors.
Purcell WT, Donehower RC. Purcell WT, et al. Curr Oncol Rep. 2002 Jan;4(1):29-36. doi: 10.1007/s11912-002-0045-8. Curr Oncol Rep. 2002. PMID: 11734111 Review.
2) Does the effect of FTI therapy depend on which ras isoform is active (ie, H-ras, K-ras4A/B, or N-ras) in cancer cells? 3) What level of farnesyltransferase inhibition is required for clinical effect? ...Although the preliminary results are encouraging, more understandin …
2) Does the effect of FTI therapy depend on which ras isoform is active (ie, H-ras, K-ras4A/B, or N-ras) in cancer cells? 3) What lev …